MA35070B1 - Traitements ophtalmiques - Google Patents
Traitements ophtalmiquesInfo
- Publication number
- MA35070B1 MA35070B1 MA36378A MA36378A MA35070B1 MA 35070 B1 MA35070 B1 MA 35070B1 MA 36378 A MA36378 A MA 36378A MA 36378 A MA36378 A MA 36378A MA 35070 B1 MA35070 B1 MA 35070B1
- Authority
- MA
- Morocco
- Prior art keywords
- sil
- compositions
- opioid
- analgesic
- pain
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 abstract 2
- 230000000202 analgesic effect Effects 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 229940005483 opioid analgesics Drugs 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 229960004380 tramadol Drugs 0.000 abstract 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 abstract 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000607 artificial tear Substances 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 229960001631 carbomer Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940014041 hyaluronate Drugs 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105731.2A GB201105731D0 (en) | 2011-04-05 | 2011-04-05 | Topical analgesics |
| GBGB1105732.0A GB201105732D0 (en) | 2011-04-05 | 2011-04-05 | Ophthalmic lubricants |
| PCT/GB2012/000330 WO2012136969A2 (en) | 2011-04-05 | 2012-04-05 | Ophthalmic treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35070B1 true MA35070B1 (fr) | 2014-04-03 |
Family
ID=46086008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36378A MA35070B1 (fr) | 2011-04-05 | 2012-04-05 | Traitements ophtalmiques |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140088199A1 (enExample) |
| EP (2) | EP2694048B1 (enExample) |
| JP (2) | JP6148664B2 (enExample) |
| KR (2) | KR102165246B1 (enExample) |
| CN (2) | CN107982211A (enExample) |
| BR (1) | BR112013025493A2 (enExample) |
| CA (1) | CA2869280C (enExample) |
| ES (1) | ES2836808T3 (enExample) |
| HK (1) | HK1254720A1 (enExample) |
| MA (1) | MA35070B1 (enExample) |
| MX (1) | MX346312B (enExample) |
| WO (1) | WO2012136969A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694048B1 (en) * | 2011-04-05 | 2020-10-07 | Optosolve Research & Development Ltd | Ophthalmic treatments |
| GB201217522D0 (en) * | 2012-10-01 | 2012-11-14 | Sharma Anant | ophthalmic therapy |
| US20160051526A1 (en) * | 2013-04-09 | 2016-02-25 | Cresset Biomolecular Discovery Ltd | The Local Treatment of Inflammatory Ophthalmic Disorders |
| ES2540151B1 (es) * | 2013-10-11 | 2016-02-29 | Farmalider S.A. | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico |
| RU2549472C1 (ru) * | 2013-12-26 | 2015-04-27 | Илья Александрович Марков | Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз |
| WO2015106068A1 (en) * | 2014-01-10 | 2015-07-16 | Manistee Partners Llc | Treatment of migraines |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| US9597328B2 (en) * | 2015-02-24 | 2017-03-21 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| US9877964B2 (en) | 2015-02-24 | 2018-01-30 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| ES2604816B1 (es) * | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
| PT3352766T (pt) * | 2015-09-24 | 2022-03-22 | Matrix Biology Inst | Composições de hialuronano de elevada elasticidade e processos para o seu uso |
| MX2018004034A (es) * | 2015-09-30 | 2018-12-19 | Edward Hoag George | Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos. |
| CN105232449B (zh) * | 2015-10-30 | 2019-04-09 | 上海昊海生物科技股份有限公司 | 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法 |
| CA3285799A1 (en) * | 2016-10-12 | 2025-11-29 | Ps Therapy, Inc. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| CN110996904A (zh) | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| MX2019014748A (es) * | 2017-06-08 | 2020-08-03 | Eye Therapies Llc | Combinaciones de brimonidina de dosis baja y usos de las mismas. |
| CN119157876A (zh) | 2017-12-15 | 2024-12-20 | 塔苏斯制药有限公司 | 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法 |
| WO2019122982A1 (en) | 2017-12-21 | 2019-06-27 | Grünenthal GmbH | Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment |
| WO2019176946A1 (ja) * | 2018-03-13 | 2019-09-19 | 参天製薬株式会社 | 点眼型洗眼薬用組成物 |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| CA3143071A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| US11504269B2 (en) | 2019-11-19 | 2022-11-22 | Jennifer L. Fabian | Therapeutic bra |
| US20230077811A1 (en) * | 2020-02-11 | 2023-03-16 | Tufts Medical Center, Inc. | Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation |
| CA3180714A1 (en) * | 2020-04-23 | 2021-10-28 | Okogen, Inc. | Treatment of viral conjunctivitis |
| CN112007028A (zh) * | 2020-09-03 | 2020-12-01 | 北京博纳致恒科技有限责任公司 | 一种复合睫状肌松弛剂的人工泪液及用途 |
| EP4297741A4 (en) * | 2021-02-26 | 2025-02-26 | Vyluma Inc. | METHODS AND FORMULATIONS FOR TOPICAL ADMINISTRATION OF GABAPENTINOIDS |
| WO2023285878A1 (en) * | 2021-07-13 | 2023-01-19 | Aviation-Ophthalmology | Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions |
| WO2024010044A1 (ja) * | 2022-07-06 | 2024-01-11 | ロート製薬株式会社 | 眼科組成物 |
| JPWO2024010039A1 (enExample) * | 2022-07-06 | 2024-01-11 | ||
| JPWO2024010045A1 (enExample) * | 2022-07-06 | 2024-01-11 | ||
| JPWO2024010040A1 (enExample) * | 2022-07-06 | 2024-01-11 | ||
| WO2025146828A1 (ja) * | 2024-01-05 | 2025-07-10 | ロート製薬株式会社 | 眼科組成物 |
| WO2025159099A1 (ja) * | 2024-01-24 | 2025-07-31 | 国立大学法人北海道大学 | 医薬組成物、眼瞼けいれん処置薬、知覚過敏またはジストニア処置薬、および症状モデルマウス |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| CA2275167C (en) * | 1996-12-16 | 2008-10-28 | Alcon Laboratories, Inc. | The topical use of kappa opioid agonists to treat ocular pain |
| US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| JP2004143157A (ja) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | 点眼剤 |
| US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| PL1768650T3 (pl) * | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| EP1611877A1 (en) * | 2004-06-28 | 2006-01-04 | Universidade de Coimbra | Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
| WO2007057508A2 (en) * | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
| US20070254841A1 (en) * | 2006-01-25 | 2007-11-01 | Ophthalmic Research Associates, Inc. | Formulations and methods for treating dry eye |
| CN101754748A (zh) * | 2007-05-24 | 2010-06-23 | 阿西克斯医疗公司 | 治疗干眼症的制剂和方法 |
| EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| EP2694048B1 (en) * | 2011-04-05 | 2020-10-07 | Optosolve Research & Development Ltd | Ophthalmic treatments |
-
2012
- 2012-04-05 EP EP12721571.3A patent/EP2694048B1/en active Active
- 2012-04-05 KR KR1020187038197A patent/KR102165246B1/ko active Active
- 2012-04-05 EP EP20200285.3A patent/EP3799866A1/en active Pending
- 2012-04-05 WO PCT/GB2012/000330 patent/WO2012136969A2/en not_active Ceased
- 2012-04-05 CA CA2869280A patent/CA2869280C/en active Active
- 2012-04-05 CN CN201711200533.4A patent/CN107982211A/zh active Pending
- 2012-04-05 ES ES12721571T patent/ES2836808T3/es active Active
- 2012-04-05 KR KR1020137029016A patent/KR20140145948A/ko not_active Ceased
- 2012-04-05 CN CN201280025096.6A patent/CN103687594A/zh active Pending
- 2012-04-05 MX MX2013011314A patent/MX346312B/es active IP Right Grant
- 2012-04-05 US US14/009,397 patent/US20140088199A1/en not_active Abandoned
- 2012-04-05 MA MA36378A patent/MA35070B1/fr unknown
- 2012-04-05 BR BR112013025493A patent/BR112013025493A2/pt not_active Application Discontinuation
- 2012-04-05 JP JP2014503208A patent/JP6148664B2/ja active Active
-
2016
- 2016-03-21 US US15/076,098 patent/US9913813B2/en active Active
-
2017
- 2017-03-07 JP JP2017043172A patent/JP6419876B2/ja active Active
-
2018
- 2018-10-26 HK HK18113731.7A patent/HK1254720A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2869280C (en) | 2020-03-10 |
| MX2013011314A (es) | 2014-03-27 |
| EP2694048B1 (en) | 2020-10-07 |
| CN107982211A (zh) | 2018-05-04 |
| WO2012136969A3 (en) | 2013-01-03 |
| JP2014513073A (ja) | 2014-05-29 |
| CN103687594A (zh) | 2014-03-26 |
| MX346312B (es) | 2017-03-15 |
| KR102165246B1 (ko) | 2020-10-13 |
| JP2017141243A (ja) | 2017-08-17 |
| WO2012136969A2 (en) | 2012-10-11 |
| JP6148664B2 (ja) | 2017-06-14 |
| KR20140145948A (ko) | 2014-12-24 |
| HK1254720A1 (zh) | 2019-07-26 |
| US20140088199A1 (en) | 2014-03-27 |
| ES2836808T3 (es) | 2021-06-28 |
| BR112013025493A2 (pt) | 2017-03-01 |
| US20160199320A1 (en) | 2016-07-14 |
| JP6419876B2 (ja) | 2018-11-07 |
| EP2694048A2 (en) | 2014-02-12 |
| EP3799866A1 (en) | 2021-04-07 |
| KR20190004815A (ko) | 2019-01-14 |
| CA2869280A1 (en) | 2012-10-11 |
| US9913813B2 (en) | 2018-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012136969A3 (en) | Ophthalmic treatments | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| WO2009077736A3 (en) | A medicament comprising a parasympathetic agonist and a sympathetic antagonist or a sympathetic agonist | |
| EP2101757A4 (en) | CONNECTION FOR TREATING OR PREVENTING DISORDERS OF THE PROSTATE AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF OF A COLON DELIVERY SYSTEM | |
| MXPA05009978A (es) | Formulacion dispersable de un agente antiinflamatorio. | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| TN2012000192A1 (fr) | N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase | |
| MA38144A1 (fr) | Compositions et procédés pour le traitement de protéinopathies | |
| MA38949A1 (fr) | Forme saline d'hydrochlorure pour inhibition d'ezh2 | |
| FR3028753B1 (fr) | Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA33743B1 (fr) | Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur | |
| MA48486B1 (fr) | Polymères liant les protons pour administration orale | |
| CL2012001402A1 (es) | Composicion farmaceutica en suspension oftalmica acuosa de administracion topica que comprende polimero de carboxivinilo, galactomanana, borato, compuesto en nanoparticulas escasamente soluble, agentes para ajustar ph y tonicidad, conservante y quelante; metodo para tratar trastornos oftalmicos, metodo para mantener viscosidad. | |
| MA35268B1 (fr) | 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie | |
| EP2796450A4 (en) | 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | |
| FR3075642B1 (fr) | Extrait de fleurs de kapokier et compositions cosmetiques, pharmaceutiques ou dermatologiques le comprenant | |
| MA29453B1 (fr) | Associations synergiques de medicaments anti-inflammatoires non steroidiens avec des ligands d'alpha-2-delta | |
| AR114216A1 (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso único diario | |
| FR2967062B1 (fr) | Utilisation d'extrait de grenade pour prevenir et/ou traiter les poches perioculaires | |
| MA31913B1 (fr) | Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations | |
| EA202090965A1 (ru) | Водные композиции биластина | |
| MA33090B1 (fr) | Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer | |
| MA37845B2 (fr) | Compositions liquides orales pédiatriques contenant du nepadutant | |
| MA33804B1 (fr) | Composition pharmaceutique pour le traitement des brûlures cutanées |